Innovative Medical's Subsidiary Bolin Brain-Computer Interface Product CyberLink AC5 Generated RMB 114,000 in Revenue Since Its October 2025 Launch

Gelonghui January 12 |Innovative HealthcareAnnouncement of Abnormal Trading Fluctuation: The company's stock price increased cumulatively by over 20% during the three consecutive trading days of January 8, 9, and 12, 2026. According to the relevant regulations of the Shenzhen Stock Exchange Trading Rules, the company’s stock is considered to be experiencing abnormal trading fluctuations. The company has noticed a high market focus on its brain-computer interface business. The company’s controlling subsidiary, Cereblink (Hangzhou) Technology Co., Ltd., was established in early 2021 and was included in the consolidated financial statements in August 2025. Its current products are mainly used for rehabilitation training of cerebrovascular disease patients in medical institutions and for assisting and enhancing motor functions at home after discharge. Cereblink’s product, Cyberlink AC5, officially launched sales in October 2025, generating revenue of 114,000 yuan in 2025; Cyberlink AM5 has completed multi-center clinical trials but did not generate revenue in 2025. In 2023 and 2024, Cereblink incurred operating losses of 6.6017 million yuan and 8.6641 million yuan, respectively.